相关实验视频

Updated: Jun 29, 2025

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

在急性髓性白血病中存在威尼托克拉克斯抗性

Sylvain Garciaz¹, Marie-Anne Hospital¹, Yves Collette¹

¹Aix-Marseille University, Inserm, CNRS, Institut Paoli-Calmettes, CRCM, 13009 Marseille, France.

|March 28, 2024

概括

威尼托克拉克斯加上阿扎西提丁可以改善急性髓性白血病 (AML) 患者的治疗结果. 然而,耐药性和复发仍然是挑战,促使人们对潜在的分子机制和新组合疗法的研究.

科学领域:

血液学血液学血液学
分子生物学分子生物学
在瘤学瘤学.

背景情况:

威尼托克拉克斯是一种BH3模仿剂,向BCL2诱导癌细胞死亡.
威尼托克拉克斯与阿扎西提丁 (VEN-AZA) 结合是一种用于急性髓性白血病 (AML) 患者的标准治疗方法,不适合进行密集化疗.
尽管有效,但对VEN-AZA的初级耐药性和复发很常见,这代表了显著的未满足的临床需求.

研究的目的:

审查目前对分子和非遗传因素的理解,这些因素有助于AML中的venetoclax耐药性.
探索旨在克服venetoclax耐药性的新兴治疗策略.

主要方法:

对调查venetoclax耐药机制的临床和临床前研究的综述.
对分子变化的分析 (例如,IDH,FLT3,TP53,BAX突变) 和非遗传因素 (例如,代谢可塑性,蛋白质表达,分化状态).

主要成果:

关键的耐药性因素包括特定的基因突变 (IDH,FLT3,TP53,BAX) 和非遗传因素,如代谢变化和蛋白质表达.
目前正在进行的临床试验正在评估三重疗法和免疫疗法以对抗耐药性.

结论:

了解venetoclax耐药性的分子驱动因素对于开发新型治疗策略至关重要.
单细胞分析有望揭示新的点,并改善AML患者的治疗结果.

关键词:

急性骨髓性白血病 (AML) 是一种急性骨髓性白血病.灭症 (apoptosis) 是一种死亡的过程.维尼托克拉克斯 (Venetoclax) 是一个

更多相关视频

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...